Webinar Summary
- Phage display technologies that can be used to isolate and develop therapeutic antibodies from immunized rabbits
- How rabbit antibodies are superior to mouse and human antibodies
- The importance of plasma cells as antibody library sources and Abwiz's technology to maximize the coverage of the antibody repertoire into antibody libraries
- How Abwiz's phage display technology can isolate rabbit antibodies with high specificity that are difficult to obtain with other methods
- How Abwiz's antibody engineering technology "Stage Enhanced Maturation (STEM)" is utilized to improve affinity, specificity, pH responsiveness, and expression
Abwiz Bio is specialized in the monoclonal antibody development through phage display technologies. In this presentation, they focus on the isolation of monoclonal antibodies from immunized rabbots using a proprietary phagemid vector and patented antibody gene cloning method, along with various selection strategies by phage display. This phagemid vector method enables optimized expression and selection of rabbit CK1 clones in bacterial cells that were previously very difficult to obtain.
This presentation also covers the humanization and developability assessment for therapeutic antibodies. Dr. Toshiaki Maruyama and Dr. Kevin Entzminger present the isolation and humanization of a lead candidate for a therapeutic target that has shown superior efficacy over the current therapeutic antibody in in vitro and in vivo experiments. They also present state-of-the-art antibody engineering technology "Stage Enhanced Maturation" (STEM) for affinity maturation, specificity control, pH responsiveness, and expression improvements. In this presentation, these scientists explain how the STEM technology works and share some examples of how it has been used successfully.
Presenters
Toshiaki Maruyama
Toshi Maruyama has over 30 years of experience in the monoclonal antibody discovery and engineering using phage display. He has contributed to the development of numerous monoclonal antibodies, including: Samalizumab®, an anti-CD200 antibody that progressed to clinical trials. KZ52, the first human neutralizing antibody against Ebola Zaire virus.
Kevin Entzminger
Kevin obtained his PhD from the Maynard lab at the University of Texas studying antibody and TCR engineering using phage display. He joined Abwiz Bio in 2015 and has since overseen dozens of successful antibody discovery and engineering campaigns. At Abwiz, he helped design and implement a fully automated phage panning robotics platform.
Sponsor
